ClinicalTrials.gg
RecruitingNCT07611708LOTUSUpdated Nov 16, 2026

Lubricin-inspired Osteoarthritis Treatment: a Unique Solution

An interventional study of ABR1 in Osteo Arthritis of the Knee, sponsored by Pleryon Therapeutics (Hangzhou) Limited. Recruiting at 1 site in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Pleryon Therapeutics (Hangzhou) Limited · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are:

  1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis?
  2. What medical problems do participants have after receiving a single injection of ABR1?

Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will

  1. Keep a stable pain treatment regimen
  2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection
  3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.
Read the detailed description

This first-in-human study is a single-site, open-label, single-arm investigation in adults with knee osteoarthritis from KL grade 2 to 4 evaluating safety and tolerability of a single, ultrasound-guided intra-articular injection of ABR1, while also observing any signals of symptom improvement over 24 weeks post-injection. All enrolled participants will receive a single administration of ABR1 intraarticularly in the target knee and will be followed per protocol for safety monitoring and clinical assessments. Participants should continue to take their medications for pre-existing medical conditions as usual during the trial. Participants will be advised that they may use study allowed rescue medication to treat worsening pain. Participants will record any rescue medication use in their Participant Diary.

Researchers will assess the incidence of adverse events, its relatedness to the device, and the incidence of any treatment-related serious adverse events through Week 12. Patient reported outcomes related to knee osteoarthritis pain will be observed up to Week 24 post injection.

02

Conditions studied

  • Osteo Arthritis of the Knee

Keywords

  • knee pain
  • intra articular
  • lubrication
03

In context

Lead sponsor

Pleryon Therapeutics (Hangzhou) Limited is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 40years of age
  2. Knee OA with Kellgren-Lawrence (KL) Grade 2 to 4 of the target knee on X-ray
  3. Inadequate pain relief with treatment, consisting of any of the following

    1. conservative non-pharmacological treatment AND/OR
    2. stable dose NSAIDs for at least the past 30 days OR
    3. use of NSAID treatment is
  4. Target knee pain on most days (at least 15 days per month in the preceding month)
  5. Symptomatic knee OA with moderate to severe pain (NRS ≥4 and \<9 on Numeric Rating Scale (NRS) with target knee significantly worse than the other knee with a minimum difference of 2-point between knees.
  6. Possess cognitive and language ability to complete and questionnaires
  7. Willingness to follow protocol instructions and maintain appointment schedule of the study
  8. Willingness to maintain their existing stable regimen (defined as the same regimen for at least the past 30 days) of complementary and non-pharmacological knee OA treatments for trial duration (if any)
  9. If participant is taking a stable regimen of NSAIDs - they are willing to maintain their existing stable regimen (defined as taking the same dose for at least the past 30 days) of NSAIDs and not anticipate to change for the duration of the study.
  10. Willingness to stop any 'as needed' (PRN) NSAIDs or paracetamol or opioids (except for protocol-permitted rescue pain medication) for the duration of the trial
  11. Willingness to stop taking any rescue pain meds 24 hours prior to scheduled follow up clinic visits (except for their stable NSAIDs therapy)

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating
  2. Other significant knee pathologies of target knee from medical history or radiographic method(s)
  3. Severe malalignment > 10 degree in the target knee (either varus or valgus) measured using standardized knee x-ray at screening or based on previous medical records
  4. Severe inflammatory arthritis or other joint disease with warm, red, and swollen knee in the target knee
  5. History of knee surgery or significant knee trauma of target knee in the past 12 months
  6. Received intraarticular injection in the targeted knee joint within the past 6 months
  7. Knee surgery or intraarticular injection in the target knee planned in the next 8 months
  8. Allergy to rescue pain medication (paracetamol)
  9. Unstable/ poorly controlled coagulopathy[CH1.1][LC1.2]
  10. Severe anxiety, depression or psychiatric disorder based on self -reported medical history
  11. Chronic pain conditions other than knee OA (e.g. cancer, fibromyalgia, pain due to hip OA, etc.) which may interfere with the outcomes of the study, at the discretion of the investigator
  12. History of or current substance abuse, self-reported
  13. Significant systemic medical comorbidities, e.g. uncontrolled diabetes or hypertension, , cancer, severe cardiovascular disease, neuropathic pain/disorder, etc.
  14. ModifiedPainDETECT Questionnaire (mPDQ) >18
  15. Current use of any non-opioids centrally acting analgesics including gabapentin, pregabalin, duloxetine, tricyclic antidepressants (e.g. amitriptyline) for pain management within 12 weeks prior to screening.
  16. Started taking oral or injectable GLP-1 products in the past 6 months as new regimen. Current use of a GLP-1 product is permitted if the participant has been on the product for > 6 months and plans to continue the product at its current stable dose for the duration of the trial.
  17. Started taking another concomitant medication within the past 12 weeks or changed dose of a concomitant medication within the past 12 weeks which could, in the opinion of the Principal Investigator or delegate, impact the participant's safety on the trial or the reliability of the outcome assessments.
  18. Participate in another clinical trial and received study intervention currently or in the past 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Received ABR1

    Received a single dose of ABR1

    Device: ABR1

Interventions

  • DeviceABR1

    Received a single dose of ABR1

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Incidence of treatment-emergent adverse events (TEAEs) through Week 12

    Time frame: from the day receiving study intervention (day 0) to 12 weeks after study intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Sun Z, Feeney E, Guan Y, Cook SG, Gourdon D, Bonassar LJ, Putnam D. Boundary mode lubrication of articular cartilage with a biomimetic diblock copolymer. Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12437-12441. doi: 10.1073/pnas.1900716116. Epub 2019 Jun 4. PubMed 31164421 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Mar 2028, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Aug 2026 → Nov 2026, primary completion Jun 2027 → Mar 2028 and completion Dec 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Nov 1, 2026was Aug 2026
Primary completionEst.
Mar 2028was Jun 2027
CompletionEst.
Jun 2028was Dec 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Royal North Shore Hospital is now Recruiting
Nov 16, 2026
Start date
Aug 2026→Nov 1, 2026 (actual)
Nov 16, 2026
Primary completion
Jun 2027→Mar 2028
Nov 16, 2026
Study completion
Dec 2027→Jun 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Royal North Shore Hospital is now Recruiting
    Start date Aug 2026→Nov 1, 2026 (now actual)
    Primary completion Jun 2027→Mar 2028
    Study completion Dec 2027→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07611708
Lead sponsor
Pleryon Therapeutics (Hangzhou) Limited
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Nov 1, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Study Coordinator
Contact
lotus.study@sydney.edu.au
0295625360
Camilla Herberstein
Contact
camilla.herberstein@sydney.edu.au
0295625360
Charis Lau, PharmD, OD, MBA
study chair · Pleryon Therapeutics Limited
David Hunter, MD
principal investigator · Royal North Shore Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Pleryon Therapeutics (Hangzhou) Limited

Start the discussion